Dihydroindolone derivatives of formula (I) and their optical and geometric isomers, and addition salts with an acid or base are disclosed, wherein the variables are as defined in the specification. The disclosure also relates to (1) the preparations of these dihydroindolone derivatives (2) the use of these dihydroindolone derivatives for the treatment of cancers, particularly cancers of the colon, breast, liver, kidneys, brain, oesophagus, melanomas, myelomas, cancers of the ovary, non-small cell lung cancers, small cell lung cancers, cancers of the prostate and pancreas, and sarcomas and (3) combination comprising these dihydroindolone derivatives with an anticancer agent comprising genotoxic agents, mitotic poisons, antimetabolites, proteasome inhibitors or kinase inhibitors.
